Comorbidities & Shared Decision-Making

Volume 2, Issue 3

Comorbidities & Shared Decision-Making

In this issue:

Which comorbidities in persons with MS are associated with poorer prognoses for longer-term disability? Can obesity-related comorbidities be reduced through behavioral interventions? What do clinicians need to know about the factors that influence patient DMT decision-making? What does the evidence say?

In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, analyzes the recent literature investigating these common concerns affecting outcomes in patients with MS.

Learning objective:

· Summarize the evidence describing the role of comorbidity in MS prognosis.

· Describe the potential impact of behavioral interventions on reducing obesity-related comorbidities.

· Identify patient factors that influence DMT decision-making, including patient preferences for their clinicians’ communication style.

Author:

Ellen Mowry, MD

Associate Professor
Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures

Dr. Mowry has disclosed that she was a principal investigator for Biogen Inc., Genzyme Corp., and SunPharma. She has also received royalty fees from UpToDate® and received free medication for a clinical trial from Teva Pharmaceuticals.

Unlabeled/Unapproved Uses

Dr. Mowry has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Program Director:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Dr. Mowry has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Length of activity:

1.0 hour Physicians

Launch date: March 15, 2019
Expiration date: March 14, 2021

Start Issue